secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2022-01-24T23:59:59+00:00
Accession:  0001193125-22-016151
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 3.03, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fluidigm secures $250M in loans and convertible preferred equity; CEO to resign
-------------------------------------------------------------------------------

- $25M term loans from Casdin and Viking at 10-16% interest, convertible into Series B preferred, subordinated to SVB loan.
- $225M private placement of Series B-1/B-2 convertible preferred stock (112,500 shares each at $1,000/share) to Casdin and Viking, subject to stockholder approval.
- CEO Stephen Christopher Linthwaite to resign at closing or by May 15, 2022; will receive $1.19M severance plus COBRA and outplacement.
- Proceeds for working capital, general corporate purposes, and potential M&A.
- Each investor gets a board seat with consent rights on major decisions including CEO hiring and M&A over $50M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000119312522016151/0001193125-22-016151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000119312522016151/d243622d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-016151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer